The association between idiopathic scoliosis and growth hormone treatment in short children
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park Mijin | - |
dc.contributor.author | Kim Yu Jin | - |
dc.contributor.author | Oh Kyeong Eun | - |
dc.contributor.author | Kang Eungu | - |
dc.contributor.author | Nam Hyo-Kyoung | - |
dc.contributor.author | Rhie Young-Jun | - |
dc.contributor.author | Lee Kee-Hyoung | - |
dc.date.accessioned | 2022-12-10T19:41:46Z | - |
dc.date.available | 2022-12-10T19:41:46Z | - |
dc.date.created | 2022-12-09 | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2287-1012 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/146831 | - |
dc.description.abstract | Purpose: Idiopathic scoliosis is the most common form of scoliosis, and the risk of onset and progression has been found to correlate with growth spurts. Therefore, treatment with recombinant human growth hormone (GH) treatment in short children may initiate and/or aggravate scoliosis. The aim of this study was to investigate the relationship between idiopathic scoliosis and GH treatment in short children.Methods: The medical records of 113 subjects seen at the participating institution between January 2010 and December 2020 and who were diagnosed with GH deficiency and small for gestational age, had idiopathic short stature, and were treated with GH for at least one year were reviewed. Scoliosis was defined as a Cobb angle greater than 10 degrees as assessed using a spine x-ray. Clinical data and laboratory findings before and 12 months after GH treatment were compared.Results: There was significant increase in height, height-standard deviation score, insulin-like growth factor 1, and insulin-like growth factor binding protein 3 (<i>p</i><0.001) with GH treatment. However, there were no significant differences in the average Cobb angle (6.2°±3.3° vs. 6.1°±3.5°, <i>p</i>=0.842) and the prevalence of scoliosis (9.7% vs. 13.3%, <i>p</i>=0.481) before and after one year of GH treatment. A comparative analysis of both initial Cobb angle and change in Cobb angle during GH treatment showed no relationship with other factors.Conclusion: Although GH treatment in short children increased height and growth velocity, it was not associated with development or aggravation of idiopathic scoliosis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 대한소아내분비학회 | - |
dc.title | The association between idiopathic scoliosis and growth hormone treatment in short children | - |
dc.title.alternative | The association between idiopathic scoliosis and growth hormone treatment in short children | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Nam Hyo-Kyoung | - |
dc.identifier.doi | 10.6065/apem.2142186.093 | - |
dc.identifier.bibliographicCitation | Annals of Pediatric Endocrinology & Metabolism, v.27, no.3, pp.207 - 213 | - |
dc.relation.isPartOf | Annals of Pediatric Endocrinology & Metabolism | - |
dc.citation.title | Annals of Pediatric Endocrinology & Metabolism | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 207 | - |
dc.citation.endPage | 213 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002880503 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Idiopathic scoliosis | - |
dc.subject.keywordAuthor | Growth hormone | - |
dc.subject.keywordAuthor | Short stature | - |
dc.subject.keywordAuthor | Growth hormone deficiency | - |
dc.subject.keywordAuthor | Small for gestational age | - |
dc.subject.keywordAuthor | Idiopathic short stature | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.